Literature DB >> 3762019

Inhibition of androgen receptor binding by natural and synthetic steroids in cultured human genital skin fibroblasts.

M Breiner, G Romalo, H U Schweikert.   

Abstract

The ability of various natural and synthetic steroids (some of which are widely used in clinical practice) to compete with dihydrotestosterone receptor binding in human genital skin fibroblasts was studied. Binding was assessed in fibroblast monolayers after incubation for 1 h at 37 degrees C with 2 nM 3H-dihydrotestosterone in the presence or absence of increasing concentrations of the steroid to be tested. Inhibition constants (Ki) were determined as the concentration of competitor-required for 50% inhibition of 3H-dihydrotestosterone binding. In addition, relative binding activity (RBA) of each test compound was calculated. Each competitor was tested in at least two different cell strains. The concentrations of unlabeled methyltrienolone (a synthetic nonmetabolizable androgen) and dihydrotestosterone for 50% inhibition of 3H-dihydrotestosterone binding were in the same order of magnitude, namely, 2 nM (2.2 respectively, 2.4 nM), whereas the affinity of testosterone was approximately one-fifth that of dihydrotestosterone. Other potent competitors for dihydrotestosterone binding were three progestins (norgestrel, gestoden, and medroxyprogesterone acetate) which have Ki values similar to testosterone. An order of magnitude lower Ki values (around 10(-7) M) were found for the androgen 17 alpha-propylmesterolone, the antiandrogen cyproterone acetate, and the progestin norethisterone acetate. Binding affinities of all other steroids to the androgen receptor were markedly lower and showed the following order of potency: estrogens (estradiol, ethinyl estradiol, diethylstilbestrol) greater than glucocorticoids as well as aromatase inhibitors and potassium canrenoate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3762019     DOI: 10.1007/bf01734339

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  16 in total

1.  Conversion of androstenedione to estrone in human fibroblasts cultured from prostate, genital and nongenital skin.

Authors:  H U Schweikert
Journal:  Horm Metab Res       Date:  1979-11       Impact factor: 2.936

2.  Comparison of the metabolism and receptor binding of testosterone and 17 beta-hydroxy-5 alpha-androstan-3-one in normal skin fibroblast cultures: influence of origin and passage number.

Authors:  G Lamberigts; P Dierickx; P De Moor; G Verhoeven
Journal:  J Clin Endocrinol Metab       Date:  1979-06       Impact factor: 5.958

3.  Abnormality of intracellular 5 alpha-dihydrotestosterone binding in simple hypospadias: studies on equilibrium steroid binding in sonicates of genital skin fibroblasts.

Authors:  B S Keenan; R L McNeel; E T Gonzales
Journal:  Pediatr Res       Date:  1984-02       Impact factor: 3.756

4.  Aromatization of androstenedione by cultured human fibroblasts.

Authors:  H U Schweikert; L Milewich; J D Wilson
Journal:  J Clin Endocrinol Metab       Date:  1976-10       Impact factor: 5.958

5.  Androgen receptor in human skin cytosol.

Authors:  I Mowszowicz; M Riahi; F Wright; P Bouchard; F Kuttenn; P Mauvais-Jarvis
Journal:  J Clin Endocrinol Metab       Date:  1981-02       Impact factor: 5.958

6.  Characterization of steroid binding specificity of the androgen receptor in human foreskin fibroblasts.

Authors:  G R Cunningham; T J Lobl; C Cockrell; T C Shao; D J Tindall
Journal:  Steroids       Date:  1983-05       Impact factor: 2.668

7.  Testosterone metabolism of fibroblasts grown from prostatic carcinoma, benign prostatic hyperplasia and skin fibroblasts.

Authors:  H U Schweikert; H J Hein; J C Romijn; F H Schröder
Journal:  J Urol       Date:  1982-02       Impact factor: 7.450

Review 8.  Cultured human skin fibroblasts: a model for the study of androgen action.

Authors:  T R Brown; C J Migeon
Journal:  Mol Cell Biochem       Date:  1981-04-13       Impact factor: 3.396

9.  A novel use of spironolactone: treatment of hirsutism.

Authors:  G Shapiro; S Evron
Journal:  J Clin Endocrinol Metab       Date:  1980-09       Impact factor: 5.958

10.  Inhibition of androgen binding in human foreskin fibroblasts by antiandrogens.

Authors:  T R Brown; S W Rothwell; C Sultan; C J Migeon
Journal:  Steroids       Date:  1981-06       Impact factor: 2.668

View more
  6 in total

1.  Characterization and expression of a cDNA encoding the human androgen receptor.

Authors:  W D Tilley; M Marcelli; J D Wilson; M J McPhaul
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

2.  Assessing the antiandrogenic properties of propyl paraben using the Hershberger bioassay.

Authors:  Ecem Özdemir; Nurhayat Barlas; Mehmet Alper Çetinkaya
Journal:  Toxicol Res (Camb)       Date:  2018-01-25       Impact factor: 3.524

Review 3.  The androgen resistance syndromes: clinical and biochemical aspects.

Authors:  H U Schweikert
Journal:  Eur J Pediatr       Date:  1993       Impact factor: 3.183

4.  Decrease in androgen binding and effect of androgen treatment in a case of X-linked bulbospinal neuronopathy.

Authors:  A Danek; T N Witt; K Mann; H U Schweikert; G Romalo; A R La Spada; K H Fischbeck
Journal:  Clin Investig       Date:  1994-11

5.  Prenatal low-dose methyltestosterone, but not dihydrotestosterone, treatment induces penile formation in female mice and guinea pigs†.

Authors:  Shanshan Wang; John Lawless; Zhengui Zheng
Journal:  Biol Reprod       Date:  2020-05-26       Impact factor: 4.285

Review 6.  Androgen actions on endothelium functions and cardiovascular diseases.

Authors:  Jing-Jing Cai; Juan Wen; Wei-Hong Jiang; Jian Lin; Yuan Hong; Yuan-Shan Zhu
Journal:  J Geriatr Cardiol       Date:  2016-02       Impact factor: 3.327

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.